Research programme: Nuclear receptor modulators - Karo PharmaAlternative Names: Nuclear receptor subfamily 4 group A member 1 modulators; Nuclear receptor subfamily 4 group A member 2 modulators; Nur77 modulators; NURR1 modulators
Latest Information Update: 21 Dec 2016
At a glance
- Originator Karo Bio
- Developer Karo Pharma AB
- Mechanism of Action Nuclear receptor subfamily 4 group A member 1 modulators; Nuclear receptor subfamily 4 group A member 2 modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders
Most Recent Events
- 07 May 2013 Early research is ongoing in Sweden
- 01 May 2012 Early research in Autoimmune disorders in Sweden (unspecified route)